BillionToOne (BLLN) closed out FY 2025 with Q4 revenue of US$96.1 million and basic EPS of US$0.14, alongside net income of US$4.4 million. This capped a year in which trailing twelve month revenue reached US$305.1 million and basic EPS sat at US$0.18. Over the past six reported quarters, the company has seen revenue move from US$38.4 million in Q3 2024 to US$96.1 million in Q4 2025. Quarterly basic EPS shifted from a loss of US$1.47 in Q3 2024 to a profit of US$0.14 in Q4 2025, signaling a very different earnings profile than a year ago. With profitability now showing through on a trailing basis after a one off hit, investors are likely to focus on how durable these margins look in the context of the growth story that has been building around the business.

See our full analysis for BillionToOne.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the most common narratives around BillionToOne and where those storylines might need a rethink.

See what the community is saying about BillionToOne

Revenue triples on a trailing basis

• On a trailing twelve month basis, revenue moved from US$71.7 million in Q4 2023 to US$305.1 million in Q4 2025, while quarterly revenue for FY 2025 ranged from US$62.8 million in Q1 and Q2 to US$96.1 million in Q4.
• Supporters with a bullish narrative point to this scaling, combined with forecast annual revenue growth of about 37.4% to 47.2%, as a backdrop for UNITY prenatal and oncology test adoption. At the same time, the fact that FY 2025 quarterly revenue held flat at US$62.8 million in Q1 and Q2 before stepping up later in the year serves as a reminder that growth has not been a straight line.

On the back of that kind of revenue expansion, bulls argue the story is far from done and want to see how those tests could compound from here: 🐂 BillionToOne Bull Case

Profitability turns positive despite one off

• Trailing twelve month basic EPS moved from a loss of US$8.45 in Q4 2023 to a profit of US$0.18 in Q4 2025, even though the period still includes an US$8.5 million one off loss that pulled last twelve month net income down to US$2.9 million.
• Critics with a bearish narrative focus on the need for heavier EMR and oncology investment and highlight that some analyst sets still work from a margin starting point of about negative 4.4%. This contrasts with FY 2025 quarterly net income already positive from Q2 through Q4 at between US$1.0 million and US$4.4 million, which shows the tension between worries about future spending and the fact that profitability has already shown up in the reported numbers.

Skeptics warn that higher costs for EMR rollouts and oncology trials could squeeze these young profits, so they stress test the thesis here: 🐻 BillionToOne Bear Case

Rich 10.8x P/S and DCF gap

• The shares trade on a P/S of 10.8x versus 1.3x for the US healthcare industry and 2.7x for peers, while the share price of US$72.17 sits well below a DCF fair value figure of about US$164.89 and below an analyst target cap of US$122.43, so valuation data sends mixed signals.
• What stands out in the bullish narrative is the view that higher growth and margins could justify these higher sales multiples. The bearish side, however, points to the same 10.8x P/S and recent share price volatility as a sign the stock already embeds a lot of optimism, which means the wide gap between US$72.17 and the US$164.89 DCF fair value and US$122.43 target becomes something you would want to double check against your own assumptions.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BillionToOne on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After all this, does the balance of risks and rewards feel clear to you, or still up for debate? Take a moment to review the numbers, pressure test the bullish and bearish angles yourself, then weigh up 3 key rewards and 2 important warning signs before deciding how this story fits in your portfolio.

See What Else Is Out There

For all the revenue momentum and fresh profitability, the combination of a rich 10.8x P/S multiple and mixed DCF versus market pricing leaves valuation feeling uncertain.

If that kind of pricing gap makes you uneasy, take a few minutes to compare BillionToOne against 47 high quality undervalued stocks and quickly zero in on ideas where the numbers look more grounded today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.